Provided by Tiger Trade Technology Pte. Ltd.

AC Immune SA

2.73
-0.0850-3.02%
Post-market: 2.730.00000.00%19:30 EDT
Volume:320.26K
Turnover:885.80K
Market Cap:277.33M
PE:-5.18
High:2.88
Open:2.84
Low:2.69
Close:2.81
52wk High:4.00
52wk Low:2.10
Shares:101.77M
Float Shares:39.19M
Volume Ratio:1.33
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5264
EPS(LYR):-0.8828
ROE:-78.53%
ROA:-16.04%
PB:6.53
PE(LYR):-3.09

Loading ...

AC Immune Jumps After US FDA Grants Fast-Track Status for Parkinson's Disease Drug

Reuters
·
Aug 11

AC Immune - Interim Results Show Safety and Immunogenicity with Early Signals of Activity for ACI-7104

THOMSON REUTERS
·
Aug 11

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-Synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (Pd)

THOMSON REUTERS
·
Aug 11

AC Immune - Full Week-100 Results from Part 1 Vacsyn Trial Expected in H2 2026

THOMSON REUTERS
·
Aug 11

AC Immune Price Target Maintained with a $8.00/Share by BTIG

Dow Jones
·
Aug 06

AC Immune SA Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Ac Immune First Half 2026 Financial and Corporate Update

Reuters
·
Aug 05

AC Immune IFRS Net Loss Narrows to CHF 12.93 Million in H1 FY26; Revenue Rises to CHF 16.23 Million

Reuters
·
Aug 05

AC Immune - Reports H1 2026 Revenue of CHF 16.20 Mln

THOMSON REUTERS
·
Aug 05

AC Immune First Half 2026 Financial and Corporate Update

THOMSON REUTERS
·
Aug 05

AC Immune - Reports Cash Resources of CHF 75.40 Mln as of June 30, 2026

THOMSON REUTERS
·
Aug 05

Swiss Stocks - Factors to Watch on August 3

Reuters
·
Aug 03

AC Immune to Present Early Human Data for First-in-class Tdp-43 PET Tracer at AAIC 2026

Reuters
·
Jul 07

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

GlobeNewswire
·
Jul 07

AC Immune Says Antibody Responses Detected in Phase 1b/2 Trial of ACI-24 in Alzheimer's Disease

MT Newswires Live
·
Jun 30

AC Immune - Aci-24 Generally Safe and Well Tolerated with no Aria-e Observed to Date

THOMSON REUTERS
·
Jun 30

AC Immune Reports Interim 12-month Data from Phase 1B/2 Abate Trial of Aci-24 in Prodromal Alzheimer’s Disease

THOMSON REUTERS
·
Jun 30

AC Immune - Final Data From Part 1 of Vacsyn Trial Expected in H2 2026

THOMSON REUTERS
·
Jun 11

AC Immune - Planned Extension to Assess Long-Term Safety and Efficacy of ACI-7104 for 2 Years

THOMSON REUTERS
·
Jun 11

Press Release: AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

Dow Jones
·
Jun 11